Prostate cancer

Zenith Epigenetics Announces Dosing of First mCRPC Patient with a Combination of ZEN-3694 + Merck’s Immune Check Point Inhibitor KEYTRUDA

Retrieved on: 
Monday, March 15, 2021
Prostate cancer, Health sciences, Organic compounds, Chemical compounds, Nonsteroidal antiandrogens, Progonadotropins, MCRPC, Enzalutamide, Therapy, Prostvac

ZEN-3694, the Companys lead therapeutic compound, is being developed for epigenetic combination therapies in multiple oncology indications.

Key Points: 
  • ZEN-3694, the Companys lead therapeutic compound, is being developed for epigenetic combination therapies in multiple oncology indications.
  • This clinical trial will evaluate the aforementioned triple combination therapy in mCRPC patients that have become resistant to a 1stline ARSI therapy.
  • Zenith Capital Corp. is a biotechnology investment company originally spun out of Resverlogix Corp. (TSX: RVX) in 2013.
  • The lead compound, ZEN-3694, is in clinical development for:
    Metastatic Castration Resistant Prostate Cancer (mCRPC) in combination with androgen receptor inhibitor, XTANDI

Kristen Bell Selects The Winners Of The Prostate Cancer Foundation's Fourth Annual TRUE Love Contest

Retrieved on: 
Thursday, March 11, 2021
Prostate cancer, Anatomy, Medical specialties, Branches of biology, Prostate Cancer Foundation, Cancer research, Prostate, Prostate Cancer Foundation of Australia, ZERO—The End of Prostate Cancer

LOS ANGELES, March 11, 2021 /PRNewswire/ --The Prostate Cancer Foundation (PCF) and actress Kristen Bell announced today the winners of the fourth annual TRUE Love Contest that honors caregivers and supporters of prostate cancer patients.

Key Points: 
  • LOS ANGELES, March 11, 2021 /PRNewswire/ --The Prostate Cancer Foundation (PCF) and actress Kristen Bell announced today the winners of the fourth annual TRUE Love Contest that honors caregivers and supporters of prostate cancer patients.
  • Caregivers and family are essential to a prostate cancer patient's mental health and recovery, but sometimes the role can go unrecognized," said Bell.
  • The Prostate Cancer Foundation (PCF) is the world's leading philanthropic organization dedicated to funding life-saving prostate cancer research.
  • The Prostate Cancer Foundation research now impacts more than 70 forms of human cancer by focusing on immunotherapy, the microbiome, and food as medicine.

Proscia and Ibex Medical Analytics Partner to Improve Prostate Cancer Diagnosis with AI-powered Workflows

Retrieved on: 
Thursday, March 11, 2021
Oncology, Health, Medical devices, Technology, Other Technology, Software, Biotechnology, Clinical medicine, Medicine, Medical specialties, Histopathology, Biopsy, Interventional radiology, Pathology, Cancer, Workflow, Prostate cancer

Through the collaboration, the partners will advance the use of computationally-enabled workflows leveraging AI, which drive accuracy, efficiency, and quality gains in routine pathology diagnosis.

Key Points: 
  • Through the collaboration, the partners will advance the use of computationally-enabled workflows leveraging AI, which drive accuracy, efficiency, and quality gains in routine pathology diagnosis.
  • View the full release here: https://www.businesswire.com/news/home/20210311005167/en/
    The standard of care for diagnosing cancer is the pathologists assessment of tissue biopsies using the microscope.
  • Proscia and Ibex have joined forces to deliver a unified software solution that powers AI-enabled workflows for prostate cancer diagnosis, helping laboratories to drive meaningful productivity and quality gains.
  • Proscia is a software company that is changing the way the world practices pathology to transform cancer research and diagnosis.

ORIC Pharmaceuticals to Present Posters on Four Programs at the 2021 American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Wednesday, March 10, 2021
Organic compounds, Chemical compounds, Chemistry, Astellas Pharma, Enzalutamide, Progonadotropins, Prostate cancer, Thioureas, Cancer research, Origin of replication, American Association for Cancer Research, Cancer

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 10, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of resistance in cancer, today announced four preclinical poster presentations at the 2021 American Association for Cancer Research (AACR) virtual annual meeting on April 10-15, 2021.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 10, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of resistance in cancer, today announced four preclinical poster presentations at the 2021 American Association for Cancer Research (AACR) virtual annual meeting on April 10-15, 2021.
  • We look forward to the continued advancements of these programs and our discovery research pipeline as we work to improve the lives of patients with cancer.
  • It has previously been demonstrated that ORIC-101 reverses GR-mediated resistance to enzalutamide and to AR degraders in preclinical prostate cancer cell lines.
  • Beyond these four product candidates, ORIC is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms.

First Patients Enrolled in Uromedica’s Adjustable Continence Therapy (ACT®) for Female Stress Urinary Incontinence (SUI) Trial

Retrieved on: 
Wednesday, March 10, 2021
FDA, General Health, Health, Medical devices, Medical specialties, Clinical medicine, Medicine, Urinary incontinence, Stress incontinence, Continence, Prostate cancer, Medical devices, Management of prostate cancer, Coital incontinence

Stress urinary incontinence is the accidental leakage of urine that can occur when sneezing, coughing, or performing physical activity.

Key Points: 
  • Stress urinary incontinence is the accidental leakage of urine that can occur when sneezing, coughing, or performing physical activity.
  • Dr. Feloney stated: ACT offers a unique approach to the management of female stress urinary incontinence.
  • I am confident that ACT will be similar to ProACT in providing relief for my patients suffering from stress urinary incontinence.
  • ProACT, Adjustable Continence Therapy for Men, was FDA-approved in 2015 for the treatment of SUI in men after prostate surgery.

Medical Diagnostic Laboratories, L.L.C., Announces New Line of Urology Testing including Prostate Cancer and Renal Cancer Hereditary Genetics

Retrieved on: 
Tuesday, March 9, 2021
Health, Cancer, Clinical medicine, Hereditary cancers, Oncology, Histopathology, Prostate cancer, Cancer syndrome, Causes of cancer, Hereditary nonpolyposis colorectal cancer

Urologic malignancies such as prostate, bladder, and renal cancers present challenges in diagnoses, treatment decisions, monitoring, and recurrence testing.

Key Points: 
  • Urologic malignancies such as prostate, bladder, and renal cancers present challenges in diagnoses, treatment decisions, monitoring, and recurrence testing.
  • Prostate, bladder, and renal cancers rank second, seventh, and ninth, respectively, in the top 10 cancers in the US based on new cancer cases.
  • In approximately 15%-20% of cases, prostate cancer can be familial, with some hereditary cancer features but no detectable mutations.
  • Hereditary genetics panels detect the presence of genes and germline pathogenic variants associated with a hereditary predisposition to prostate cancer and renal cancer.

Veru to Present at the Oppenheimer 31st Annual Healthcare Conference

Retrieved on: 
Tuesday, March 9, 2021
Breast cancer, Triple-negative breast cancer, Prostate cancer, Management of prostate cancer, Cancer, Anatomy, Health

MIAMI, March 09, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, today announced that the Company will present at the Oppenheimer 31st Annual Healthcare Conference.

Key Points: 
  • MIAMI, March 09, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, today announced that the Company will present at the Oppenheimer 31st Annual Healthcare Conference.
  • The presentation will be available through the Conference on Tuesday, March 16th at 3:10 p.m.
  • Veru Inc. is an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer and breast cancer.
  • The Veru breast cancer pipeline includes enobosarm for AR+/ER+/HER2- metastatic breast cancer and VERU-111 for taxane resistant metastatic triple negative breast cancer.

GT Biopharma Announces Preclinical Results For Its ROR1 TriKE™ As A Treatment For Prostate Cancer

Retrieved on: 
Monday, March 8, 2021
Prostate cancer, Branches of biology, Cancer research, Cancer, Medicine, Urology, Tyrosine kinase receptors, ROR1, Virotherapy, LNCaP, VCaP, DU145

BEVERLY HILLS, Calif., March 8, 2021 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage biopharmaceutical company focused on disruptive, target-directed Natural Killer (NK) cell engager immunotherapy technologies (TriKE) for cancer, announces preclinical results for its ROR1 TriKE product candidate as a prospective therapy for the treatment of prostate cancer.

Key Points: 
  • BEVERLY HILLS, Calif., March 8, 2021 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage biopharmaceutical company focused on disruptive, target-directed Natural Killer (NK) cell engager immunotherapy technologies (TriKE) for cancer, announces preclinical results for its ROR1 TriKE product candidate as a prospective therapy for the treatment of prostate cancer.
  • Targeting ROR1 on cancer cells with TriKE and redirecting NK cells to attack and kill cancer cells expressing ROR1, could result in a therapeutic treatment that limits the metastatic potential and invasiveness of certain solid tumor cancers.
  • The ROR1 TriKE was evaluated in several preclinical models of prostate cancer, and was found to be effective at promoting NK cell killing of multiple prostate cancer cells including LnCAP, C4-2, PC-3, DU-145, VCaP and 22RV1.
  • "We plan to evaluate the ROR1 TriKE in additional IND-enabling preclinical studies with the goal of transitioning to a Phase I/II clinical trial."

Quibim Receives FDA 510(k) Clearance for qp-Prostate New AI Solution for Prostate MRI Analysis

Retrieved on: 
Thursday, March 4, 2021
Anatomy, Branches of biology, Medical physics, Medical imaging, Histopathology, Radiology, Prostate cancer, Prostate, Magnetic resonance imaging, Prostate biopsy, Phantom structure

Quibim set out to transform prostate diagnosis and monitoring by developing a new non-invasive imaging tool using MRI data and advanced computer models to investigate the prostate anatomy in extreme detail.

Key Points: 
  • Quibim set out to transform prostate diagnosis and monitoring by developing a new non-invasive imaging tool using MRI data and advanced computer models to investigate the prostate anatomy in extreme detail.
  • "MRI is the perfect modality for prostate evaluation, however, only 5% of radiologists are trained to interpret prostate MRI data," explained Prof. Luis Mart-Bonmat, Quibim co-founder.
  • The software runs on a standard "off-the-shelf" workstation and can be used to perform image viewing, processing and analysis of prostate MR images.
  • Quibim, a company with its headquarters in Valencia, Spain, is a global leader in whole-body medical imaging analysis.

Pre-clinical data on HOOKIPA’s alternating 2-vector cancer therapeutics published in Cell Reports Medicine

Retrieved on: 
Thursday, March 4, 2021
Branches of biology, Histopathology, Medical specialties, Prostate cancer, Clinical medicine, Cancer immunotherapy, Glutamate carboxypeptidase II

The pre-clinical data published in Cell Reports Medicine underscore the potential of our engineered arenavirus platform to redefine success in cancer immunotherapy.

Key Points: 
  • The pre-clinical data published in Cell Reports Medicine underscore the potential of our engineered arenavirus platform to redefine success in cancer immunotherapy.
  • The data in this peer-reviewed publication provide the scientific substantiation for the ongoing clinical trial of the alternating 2-vector therapy for Human Papillomavirus 16-positive (HPV16+) cancers as well as for advancing to prostate cancer.
  • Pre-clinical data featured in the article showed that intravenous, alternating administration of two different replicating arenaviral vectors that express the same antigen induces potent T cell response, exceeding 50% of the circulating T cell pool, and robust anti-tumor activity.
  • HOOKIPAs HB-300 program for prostate cancer also uses the LCMV and PICV arenaviral backbones directed against three validated antigens for prostate cancer: PAP, PSA, and PSMA.